ArgusEye

At ArgusEye, our patented technology leverages nanoplasmonic sensing and fiber optics to create Localized Surface Plasmon Resonance (LSPR), a powerful phenomenon with transformative potential in biosensing.   Hear from our Senior R&D Engineer, Thuy Tran, about how LSPR works and how it can be used for biosensing. #LSPR #Biosensing #Innovation

Meet us in Stockholm at BIO-Europe!   Our Co-founder & CEO Dr. Erik Martinsson, COO Nathalie Elsässer, and Product Manager Motasam Majedy are in Stockholm for the BIO-Europe partnering event, running from today through Wednesday. We’re eager to connect with collaborators who share our passion for accelerating bioprocessing and transforming the biopharma industry. Together, we can drive meaningful change! 🚀   Come visit us at Booth 117—we would love to chat! #BIOEurope #Biopharma #Innovation #Acceleration

Join us at BIO-Europe in Stockholm on November 4-6!🌟   We’re excited to be in Stockholm for the BIO-Europe partnering event on November 4-6, where we aim to connect with like-minded partners. We seek collaborators who share our passion for accelerating bioprocessing and transforming the biopharma industry. Together, we can make a significant impact. At booth 117, you will meet our CEO, Dr. Erik Martinsson, COO Nathalie Elsässer, and Product Manager Motasam Majedy. We invite you to stop by and chat with us. We look forward to seeing you there! #BIOEurope #Biopharma #Innovation #Acceleration

🌟We are hiring!🌟   We are currently looking for an Embedded Software Engineer to join our team. The recruitment process is ongoing, so don't hesitate to submit your application. Apply today and join us in our journey to transform how biopharmaceuticals are developed and produced through our unique sensor technology! #Hiring #EmbeddedSoftwareEngineer #Sensors #Team #Expansion #Career

AugaOne™ is a robust stand-alone sensor system designed to revolutionize your product development process. By integrating the system into your process development, it transitions from time-consuming tests to automatied real-time, in-line data collection.   The system is primarily designed for biopharma groups working on downstream monoclonal antibody (mAb) process development. Currently, this process relies on time-consuming and labor-intensive, off-line testing. With AugaOne™, these tests are automated, enabling significantly faster process development.   Incorporating the sensor system into your process development reduces manual handling and shortens each experiment cycle by days, as well as the overall development time by years, leading to significant cost savings and optimal resource allocation.   AugaOne™ offers a hassle-free plug-and-play setup and real-time response. No more waiting for experiment results – feedback is received in just a second, providing fast, accurate data unaffected by time or sample processing. This translates into a more stable process requiring smaller margins. Reach out to our COO, Nathalie Elsässer, at nathalie.elsasser@arguseye.se to explore how AugaOne™ can revolutionize your process development and drive unprecedented efficiency and cost savings. 🚀     #AugaOne #AugaPlatform #Biopharma #BiotechInnovation #BiopharmaInnovation #DrugDevelopment #RealTimeData #DownstreamProcessing #mAb #MonocolonalAntibodies

🚀 At ArgusEye, we are dedicated to revolutionizing biopharmaceutical processing with our Auga™ platform. By offering real-time monitoring of critical parameters, we provide rapid and accurate quality data within seconds, driving faster and more efficient production of biological drugs. Discover how Auga™ is accelerating the future of biotech 👇 https://lnkd.in/d8CsAv4c #biotechinnovation #biopharma #processoptimization #qualitycontrol #augaplatform

🌟 Two rewarding and valuable weeks on the East Coast of the US concluded with a successful pitch win for ArgusEye!   After a successful start at the BioProcess International conference in Boston, our COO Nathalie Elsässer, has been in New York for a few days. There, she took part in the 2024 InnovativeNordics Acceleration Program, where ArgusEye was chosen as one of the participating companies.   The program has provided valuable opportunities, productive meetings, and new insights. We have engaged in activities and gatherings, forming good contacts that can help us quickly establish ourselves ahead of an upcoming US launch. We also had the opportunity to meet companies that have gone through a similar expansion journey, as well as companies that specialize in bringing international companies to the US. Through the program, we have received relevant leads to potential clients and insights into various aspects, from tax law to employment.   On the last day, we had company pitches, where participants had the chance to pitch in front of industry experts, investors, and other relevant companies. Elsässer made a great pitch, resulting in a win for ArgusEye! As part of our award, we received a SACCNY membership and an office location in New York – the perfect kick-start to our US-expansion.   We are excited about the next step in our expansion and establishing our cutting-edge technology in the US market. 🚀

✨Say hello to Jakob, our latest addition to the ArgusEye team!✨   Jakob is one of our new R&D Lab Engineers. With a master's degree in sensors and materials, he will bring valuable knowledge and experience to our development team.   Welcome to ArgusEye, Jakob – we are thrilled to have you with us!   Get to know Jakob 👇   #welcome #team #expansion #innovation 

✨ This year's edition of BioProcess International has now come to an end. It has been a valuable couple of days, filled with informative sessions, networking opportunities, and great encounters. Yesterday, Prof. Daniel Aili, Co-founder and Chairman of ArgusEyes, took the stage to discuss the Real-Time Analytical Solution for Optimizing Upstream mAb Bioprocessing. The response was fantastic, marked by valuable and engaging discussions.   These days have not only provided us with new insights, but have also confirmed the challenges and needs that the pharmaceutical industry is currently facing. These are challenges and needs that we at ArgusEye are actively working to address.   “Monoclonal antibodies (mAbs) still dominates the industry, whilst there there is a growing focus on cell and gene therapy. At the same time continuous manufacturing is being implemented more rapidly than before. As a stepping stone, intensified processing and automation are becoming increasingly important, and many technologies that were previously only presented in the literature are now being put into practice. In this, the need for accurate real-time data throughout the process is becoming increasingly important to achieve more efficient and controlled processes” – COO Nathalie Elsässer.   Thank you to everyone who took the time to visit our booth and talk to us. Special thanks to BioProcess International for organizing a great conference. The journey continues for ArgusEyes as our COO, Nathalie Elsässer, heads to New York to participate in the 2024 InnovativeNordics Acceleration Program. This marks an important step in our expansion in the US market.   We look forward to meeting you! Please feel free to contact Nathalie to schedule a meeting.   #bioprocessinternational #BPI2024 #BPICONF #biotechweekboston #innovation #expansion #InnovativeNordics2024

Touchdown Boston and BioProcess International! ✈️ We are currently at BioProcess International in Boston and are eagerly anticipating the opportunities in the days ahead. Our COO Nathalie Elsässer, Application Scientist Ana Pinheiro, Ph.D., and Co-founder and Chairman Prof. Daniel Aili have set up our booth and are excited to meet many of you! 📍Visit us at booth 900 and be sure to catch Prof. Daniel Aili's speech on September 26. #bioprocessinternational #BPI2024 #BPICONF #biotechweekboston #innovation #biopharma